Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cardiovascular technologies

- PMLiVE

GSK hit as darapladib flunks phase III test

Heart disease drug disappoints in late-stage trial

- PMLiVE

Janssen buys hepatitis C candidate from GSK

J&J subsidiary acquires rights to NS5A inhibitor

- PMLiVE

J&J hit by more recalls

Withdraws 200,000 bottles of cough drops in US

- PMLiVE

J&J files rare blood disorder drug siltuximab in US and EU

Orphan drug to be assessed for use in the treatment of multicentric Castleman disease

EU flag

Europe backs two blood cancer treatments

Approvals for J&J’s Velcade and Celgene’s Imnovid for treatment of multiple myeloma

- PMLiVE

J&J gets pharma Q2 results off to a flying start

OTC recovery and Synthes acquisition help boost sales performance

- PMLiVE

J&J files ‘breakthrough’ drug ibrutinib in US

FDA to assess drug in lymphoma and leukaemia

- PMLiVE

AZ in atherosclerosis education drive during US Heart Month

Encouraging the public to learn more about the causes of heart disease

- PMLiVE

Interview: Cesar Rodriguez, Janssen

Managing director of Janssen UK & Ireland, Cesar Rodriguez is relishing being in the UK market, after years working across Europe and North Africa

- PMLiVE

Merck drops plans to file Tredaptive in US

Pharma company also says cardiovascular drug should not be prescribed to new patients in Europe

- PMLiVE

WHO launches framework to monitor non-communicable diseases

Will measure success of efforts to reduce rates of cancer, diabetes, lung conditions and heart disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links